NCT02376036 - Phase 1 Study of MGD010 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions

Healthy Subjects

Interventions

DRUG

MGD010

MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.

DRUG

Placebo

Placebo comparator.

BIOLOGICAL

Hepatitis A vaccine

Hepatitis A vaccine, inactivated

Trial Locations (1)

21225

PAREXEL Baltimore Early Phase Clinical Unit, Baltimore